Skip to main content
. 2020 May 6;37(2):240–249. doi: 10.5114/ada.2020.94842

Table 1.

Study sample characteristics. Basic demography and anthropometry of the study population and subpopulations according to the treatment modality and presence of CRSwNP (Pearson χ2 and Mann-Whitney U test)

Parameter Total Therapy CRSwNP
Conv. therapy OMA P-value No Yes P-value
Sample size, n 48 38 10 33 15
Sex (male/female) 19/29 14/24 5/5 0.449 (a) 11/22 8/7 0.189 (a)
Age (mean/SD) [years] 47.7/12.5 49/13 44/10 0.309 (b) 47/13 50/12 0.338 (b)
Height (mean/SD) [cm] 170/10 170/10 170/10 0.851 (b) 169/9 170/12 0.577 (b)
Weight (mean/SD) [kg] 79/20 78/21 83/17 0.445 (b) 78/22 82/13 0.225 (b)
BMI (mean/SD) [kg/m2] 27.3/5.62 26.9/5.57 28.7/5.9 0.430 (b) 26.8/6.13 28.3/4.29 0.161 (b)
Obesity (yes/no) 10/38 6/32 4/6 0.093 (a) 7/26 3/12 0.924 (a)
Exacerbation rate (mean/min./max.) 1.91/0/12 1.91/0/12 1.90/0/10 0.742 (b) 1.41/0/10 2.93/0/12 0.093 (b)
OMA therapy duration (mean/min./max.) [months] 26/3/60 0 26/3/60 5.15/0/48 5.67/0/60 0.938 (b)
Comorbidities in general (yes/no) 46/2 37/1 9/1 0.299 (a) 32/1 14/1 0.559 (a)
Smoking status (yes/no) 2/46 2/36 0/10 0.459 (a) 1/32 1/14 0.559 (a)
Airway obstruction (yes/no) 30/18 25/13 5/5 0.359 (a) 20/13 10/5 0.688 (a)
AERD (yes/no) 9/39 6/32 3/7 0.306 (a) 3/30 6/9 0.011 (a)
Atopy status (yes/no) 39/9 29/9 10/0 0.088 (a) 27/6 12/3 0.881 (a)
Atopic eczema (yes/no) 13/35 9/29 4/6 0.302 (a) 12/21 1/14 0.032 (a)
Allergen exposure (yes/no) 15/33 14/24 1/9 0.103 (a) 11/22 4/11 0.644 (a)
Asthma severity (n) Mild 4 4 0 0.041 (a) 4 0 0.428 (a)
Moderate 9 9 0 7 2
Severe 6 6 0 4 2
Severe Refractory 29 19 10 18 11
Asthma control (n) Controlled 7 6 1 0.967 (a) 7 0 0.068 (a)
Partly controlled 27 21 6 19 8
Uncontrolled 10 8 2 6 4
Exacerbation 4 3 1 1 3
Asthma phenotype (n) Eosinophilic allergic 37 27 10 0.153 (a) 25 12 0.097 (a)
Eosinophilic non-allergic 5 5 0 2 3
Neutrophilic 6 6 0 6 0

(a) Pearson χ2, (b) Mann-Whitney U test.